The Market Edge—New Bupe Rules, Ginger Gets Network Status, Walmart Partners Up

Navigation is all about keeping an eye on the guideposts and avoiding the obstacles ahead. This week brought more market developments that will reshape the landscape. After postponing the Trump Administration rules for expanding prescriptive ability for buprenorphine to treat opioid use disorder (OUD), the Biden Administration gave a green light to the concept. The proposed new practice guidelines are effective immediately and allow prescribers who are state licensed and registered by the Drug Enforcement Administration (DEA) to prescribe certain controlled substances with an exemption on training and certification (see HHS Releases New Buprenorphine Practice Guidelines, Expanding Access To Treatment . . .